Egyptian Drug Authority Authorizes Biomerica's Complete Screening Test Portfolio [Yahoo! Finance]
Biomerica, Inc. (BMRA)
NASDAQ:AMEX Investor Relations:
biomerica.com/company/investor.asp
Company Research
Source: Yahoo! Finance
• Portfolio includes tests for colorectal disease, breast self exam, prostate disease, kidney disease, and H. pylori infection • Designed for early detection of conditions that are related to the most common cancers and chronic diseases • Rapid, easy-to-use, and cost-effective screening for mass and individual use IRVINE, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced today that the Egyptian Drug Authority (EDA) has granted authorization for Biomerica's complete portfolio of rapid tests, enabling broad access to simple, rapid, and affordable early detection tools for conditions associated with cancers and chronic diseases across Egypt. This authorization allows Biomerica's screening products to be marketed and distributed throughout Egypt, supporting early identification of conditions associated with colorectal, breast, and prostate cancers, as well as chronic diseases including kidney dis
Show less
Read more
Impact Snapshot
Event Time:
BMRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRA alerts
High impacting Biomerica, Inc. news events
Weekly update
A roundup of the hottest topics
BMRA
News
- Biomerica Reports Second Quarter Fiscal 2026 Financial ResultsGlobeNewswire
- Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test [Yahoo! Finance]Yahoo! Finance
- Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS TestGlobeNewswire
- Egyptian Drug Authority Authorizes Biomerica’s Complete Screening Test PortfolioGlobeNewswire
- Biomerica's inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS [Yahoo! Finance]Yahoo! Finance
BMRA
Sec Filings
- 1/28/26 - Form 4
- 1/14/26 - Form 10-Q
- 12/31/25 - Form 4
- BMRA's page on the SEC website